Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation As Shares Show Firm Recent Momentum

Simply Wall St.02-16

AdvertisementWhy Shanghai Henlius Biotech Is On Investors’ Radar Shanghai Henlius Biotech (SEHK:2696) has recently caught investor attention, with the share price moving over the past week, month and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611483621?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-16 19:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611483621","market":"nz","top_or_hot":-1,"title":"Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation As Shares Show Firm Recent Momentum","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Shanghai Henlius Biotech Is On Investors’ Radar Shanghai Henlius Biotech (SEHK:2696) has recently caught investor attention, with the share price moving over the past week, month and ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-as-sha\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation As Shares Show Firm Recent Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Shanghai Henlius Biotech (SEHK:2696) Valuation As Shares Show Firm Recent Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-16 19:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-as-sha><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Shanghai Henlius Biotech Is On Investors’ Radar Shanghai Henlius Biotech (SEHK:2696) has recently caught investor attention, with the share price moving over the past week, month and ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-as-sha\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306685.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-as-sha","article_id":"2611483621","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/assessing-shanghai-henlius-biotech-sehk2696-valuation-as-sha","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611483621","pubTimestamp":1771240274,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Shanghai Henlius Biotech Is On Investors’ Radar\nShanghai Henlius Biotech (SEHK:2696) has recently caught investor attention, with the share price moving over the past week, month and past 3 months, prompting a closer look at its fundamentals and returns.\nSee our latest analysis for Shanghai Henlius Biotech.\nAt the current share price of HK$70.5, Henlius has shown firm momentum, with a 10.5% 90 day share price return and a very large 1 year total shareholder return. Together, these figures...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","02696":"复宏汉霖","LABU":"三倍做多标普生物-Direxion","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"评估上海复宏汉霖生物科技（SEHK：2696）的估值，因为该股近期表现出强劲的势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02696":0.9,"LABU":1.5},"content_text":"AdvertisementWhy Shanghai Henlius Biotech Is On Investors’ Radar Shanghai Henlius Biotech (SEHK:2696) has recently caught investor attention, with the share price moving over the past week, month and past 3 months, prompting a closer look at its fundamentals and returns. See our latest analysis for Shanghai Henlius Biotech. At the current share price of HK$70.5, Henlius has shown firm momentum, with a 10.5% 90 day share price return and a very large 1 year total shareholder return. Together, these figures suggest investors are reassessing its growth prospects and risk profile. If you are looking beyond a single biotech name, this could be a good moment to see what else is moving in healthcare by checking our 106 healthcare AI stocks as a potential source of new ideas. With Henlius trading at HK$70.5, and given both an intrinsic discount and a large gap to analyst targets, the key question is whether the shares are still undervalued or if the market is already pricing in future growth. Preferred P/E of 41.1x: Is it justified? On a P/E of 41.1x at HK$70.5, Shanghai Henlius Biotech screens as expensive against its own fair P/E estimate, yet still cheaper than many biotech peers. The P/E ratio compares the current share price to earnings per share, so a higher multiple often reflects the market paying up for current profitability or expected earnings growth. For a commercial stage biotech with positive earnings and a portfolio focused on oncology and autoimmune diseases, investors often pay attention to this yardstick when weighing growth against current profitability. Simply Wall St’s fair P/E estimate sits at 20.8x, which is much lower than the current 41.1x. This means the market is putting a richer tag on Henlius earnings than that fair ratio implies. At the same time, Henlius trades on a lower P/E than the peer average of 78.1x and roughly in line with the Asian biotech industry average of 41.4x. As a result, relative pricing is not stretched in sector terms even if it looks full against the internal fair ratio level the market could move towards. Explore the SWS fair ratio for Shanghai Henlius Biotech Result: Price-to-Earnings of 41.1x (OVERVALUED) However, you also have to weigh the execution risk around its broad drug pipeline and the possibility that current P/E expectations may be too optimistic if earnings momentum stalls. Find out about the key risks to this Shanghai Henlius Biotech narrative. Another View: DCF Signals Deep Discount While the 41.1x P/E at HK$70.5 looks rich against Henlius fair ratio of 20.8x, our DCF model points the other way. On that approach, the shares trade 62.1% below an estimated cash flow value of HK$186.21, which frames current pricing as a potential discount rather than excess. With one method indicating expensive and another indicating cheap, which risk are you more comfortable with: paying up on earnings or trusting long term cash flow assumptions, Look into how the SWS DCF model arrives at its fair value. 2696 Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 224 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Shanghai Henlius Biotech Narrative If you look at this and reach a different conclusion, or would rather test your own assumptions, you can build a personalised view in just a few minutes: Do it your way A great starting point for your Shanghai Henlius Biotech research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Ready For More Investment Ideas? If Henlius has sparked your curiosity, do not stop here. Put that momentum to work by scanning other opportunities that match the kind of portfolio you want.  Target potential mispricing by checking our list of 224 high quality undervalued stocks that pair solid fundamentals with attractive entry points. Strengthen your income stream by reviewing 448 dividend fortresses that focus on companies offering higher yields with a focus on resilience. Protect your downside by using the 324 resilient stocks with low risk scores to spot companies with more stable risk profiles before others catch on.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611483621","isCrawlerRequest":true}